Document is current
Any future updates will be listed below
-
Authors
Wijstma, Eline S.
Groot Bruinderink, Marije L.
Jongen, Vita W.
Boyd, Anders C.
Blitz, Laura
van Bokhoven, Colette
Woudstra, Joey
Vermey, Koenraad
Boers, Sophie
Götz, Hannelore M.
van Harreveld, Frenk
Prins, Maria
Hoornenborg, Elske
Davidovich, Udi
Schim van der Loeff, Maarten F.
-
Funding
Funding for this research was provided by:
Stichting Aidsfonds (P-42701 and P- 54201)
Gilead Sciences (21341)
GGD Amsterdam (2021-5 and 2022-2)
- License Information
-
More Information
Article History
Received: 28 January 2026
Accepted: 20 May 2026
First Online: 4 June 2026
Declarations
:
: The EZI-PrEP Trial was approved by the medical ethics committee of the Amsterdam University Medical Center, file number 2020_154 - NL74494.018.20. The trial has been registered with ClinicalTrials.gov, trial number NCT05093036 ( ). Written informed consent for study participation was obtained from all participants as part of the eligibility screening procedure.
: Written informed consent for publication was obtained from all participants as part of the eligibility screening procedure.
: UD received unrestricted research grants from Gilead Sciences, and participated in Advisory boards of ViiV HealthCare & Gilead Sciences, all fees and grants paid to his institute. MFSvdL participated in Advisory Boards of Merck Sharp & Dohme, for which fees were paid to his institute. MFSvdL received a research grant from GlaxoSmithKline, paid to his institute. EH received unrestricted research grants from Gilead Sciences, paid to her institute. MP received unrestricted research grants and speaker/advisory fees from Gilead Sciences and Merck Sharp & Dohme, all paid to her institute. AB received speaker’s fees from Gilead Sciences. All other authors declare no competing interests.
